151 related articles for article (PubMed ID: 29389139)
1. Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Neburkova J; Sedlak F; Zackova Suchanova J; Kostka L; Sacha P; Subr V; Etrych T; Simon P; Barinkova J; Krystufek R; Spanielova H; Forstova J; Konvalinka J; Cigler P
Mol Pharm; 2018 Aug; 15(8):2932-2945. PubMed ID: 29389139
[TBL] [Abstract][Full Text] [Related]
2. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
3. MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.
Airan RD; Foss CA; Ellens NP; Wang Y; Mease RC; Farahani K; Pomper MG
Mol Imaging Biol; 2017 Feb; 19(1):24-30. PubMed ID: 27481359
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
6. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
[TBL] [Abstract][Full Text] [Related]
7. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
8. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Pavlicek J; Ptacek J; Cerny J; Byun Y; Skultetyova L; Pomper MG; Lubkowski J; Barinka C
Bioorg Med Chem Lett; 2014 May; 24(10):2340-5. PubMed ID: 24731280
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
12. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors.
Choy CJ; Fulton MD; Davis AL; Hopkins M; Choi JK; Anderson MO; Berkman CE
Chem Biol Drug Des; 2013 Nov; 82(5):612-9. PubMed ID: 23773397
[TBL] [Abstract][Full Text] [Related]
13. GCPII imaging and cancer.
Foss CA; Mease RC; Cho SY; Kim HJ; Pomper MG
Curr Med Chem; 2012; 19(9):1346-59. PubMed ID: 22304713
[TBL] [Abstract][Full Text] [Related]
14. Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Zhu C; Bandekar A; Sempkowski M; Banerjee SR; Pomper MG; Bruchertseifer F; Morgenstern A; Sofou S
Mol Cancer Ther; 2016 Jan; 15(1):106-113. PubMed ID: 26586724
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization.
Derlin T; Thiele J; Weiberg D; Thackeray JT; Püschel K; Wester HJ; Aguirre Dávila L; Larena-Avellaneda A; Daum G; Bengel FM; Schumacher U
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2213-2219. PubMed ID: 27609368
[TBL] [Abstract][Full Text] [Related]
16. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
17. A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry.
Choy CJ; Berkman CE
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1690-3. PubMed ID: 26873576
[TBL] [Abstract][Full Text] [Related]
18. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Tykvart J; Schimer J; Jančařík A; Bařinková J; Navrátil V; Starková J; Šrámková K; Konvalinka J; Majer P; Šácha P
J Med Chem; 2015 May; 58(10):4357-63. PubMed ID: 25923815
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
20. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]